Browsing Category
Pharma Industry News
4535 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Lexeo’s second cardiac gene therapy gains FDA support ahead of year-end update
LX2020 gains FDA RMAT status after early heart gene therapy data, strengthening Lexeo’s regulatory path ahead of a key 12-month update.
Early lung cancer responses push ACR-2316 into a broader randomized trial
ACR-2316 enters randomized expansion after durable lung cancer activity. Read how the six-tumor study could reshape Acrivon’s outlook.
Harmony’s next growth engine takes shape as BP-205 clears its first clinical test
BP-205 shows a 25-hour half-life as Harmony uses record WAKIX revenue to fund its next neuroscience growth engine amid rising orexin competition
One-time gene correction therapy BEAM-302 reaches pivotal AATD testing
BEAM-302 enters pivotal AATD testing as Beam Therapeutics targets accelerated approval with $1.2 billion in cash and new data due in September.
FDA opens first human test for BriaCell’s prostate cancer cell therapy
Bria-PROS+ gains FDA clearance for its first prostate cancer trial, expanding BriaCell’s off-the-shelf cellular immunotherapy platform.
NIH backs Greenstone Biosciences iPSC and AI programme for Duchenne cardiomyopathy
Greenstone Biosciences has secured a National Institutes of Health R61 award to discover potential treatments for cardiac fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy, extending its patient-derived stem-cell drug discovery strategy into one of the disease’s most consequential complications.
Greenstone Biosciences wins NHLBI R61 award to identify small-molecule treatments for DMD heart disease
Greenstone Biosciences has secured a $625,968 National Heart, Lung, and Blood Institute (NHLBI) R61 grant to combine patient-derived stem cells, proteomics and artificial intelligence in the search for small-molecule treatments for cardiac fibrosis in Duchenne muscular dystrophy (DMD). The award validates the company’s human-cell-based discovery platform, but target selection, compound validation and progression into the programme’s R33 phase remain critical tests.
Weekly RM-718 shows double-digit BMI reduction in small hypothalamic obesity trial
Rhythm Pharmaceuticals reports an 11.6% BMI reduction with weekly RM-718 as it expands a rare obesity franchise built around three treatments.
Could monthly treatment replace burdensome peanut allergy dosing? Aravax may soon have an answer
Aravax gains FDA Fast Track status for PVX108 as Phase 2 peanut allergy data approach and preparations for a possible Phase 3 program advance.
Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter
Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.